Kronos Bio, Inc. (NASDAQ:KRON - Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 611,600 shares, a decline of 18.2% from the March 15th total of 748,000 shares. Based on an average daily volume of 188,000 shares, the days-to-cover ratio is currently 3.3 days. Approximately 1.6% of the company's shares are short sold.
Kronos Bio Stock Performance
NASDAQ:KRON traded down $0.02 during trading hours on Thursday, hitting $0.86. The stock had a trading volume of 68,737 shares, compared to its average volume of 245,261. The business's 50 day moving average is $0.89 and its 200-day moving average is $0.94. The company has a market cap of $52.49 million, a price-to-earnings ratio of -0.60 and a beta of 1.78. Kronos Bio has a one year low of $0.69 and a one year high of $1.60.
Kronos Bio (NASDAQ:KRON - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.13). Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%. The business had revenue of $2.27 million for the quarter, compared to the consensus estimate of $1.00 million. On average, sell-side analysts anticipate that Kronos Bio will post -1.36 EPS for the current fiscal year.
Institutional Investors Weigh In On Kronos Bio
Several large investors have recently made changes to their positions in the stock. Peapod Lane Capital LLC acquired a new position in shares of Kronos Bio during the 4th quarter worth approximately $534,000. Gilead Sciences Inc. bought a new position in shares of Kronos Bio in the fourth quarter worth $179,000. Deltec Asset Management LLC bought a new stake in shares of Kronos Bio during the 4th quarter worth approximately $190,000. Kennedy Capital Management LLC increased its stake in Kronos Bio by 8.7% in the fourth quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company's stock valued at $142,000 after acquiring an additional 12,007 shares during the last quarter. Finally, GTS Securities LLC acquired a new position in Kronos Bio during the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 64.09% of the company's stock.
Kronos Bio Company Profile
(
Get Free Report)
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Featured Stories
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
